Program
JAK2 Inhibitor TQ05105
Also written as “TQ05105 tablets”, “TQ05105” and “TQ05105 Tablets”.
In Sino Biopharmaceutical’s pipeline, JAK/ROCK抑制剂
. Its studies are mostly in Primary Myelofibrosis · Bronchiolitis Obliterans Syndrome · Myeloproliferative Disorders · Lymphoma, Follicular · Lymphohistiocytosis, Hemophagocytic, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 167 open or running | phase 2since Jun 21, 2021 | Mar 26, 2020 | Dec 2026phase 1 · NCT07708272 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQ05105
, phase 4, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Mar 26, 2020.
- Apr 7, 2020Phase 1 study in Myeloproliferative DisordersNCT04339400 · 79 enrolled · China
- Jun 21, 20212 phase 2 studiesNCT04944043, NCT04941404
- Aug 23, 2021Phase 2 study in Lymphoma, FollicularNCT05020652 · 107 enrolled · China
- Jul 7, 2023Phase 1 study in Primary MyelofibrosisNCT05982106 · 16 enrolled · China
- Aug 30, 2023Phase 1 study in Primary MyelofibrosisNCT06024915 · 40 enrolled · China
- Nov 2, 2023Phase 2 study in Primary MyelofibrosisNCT06122831 · 92 planned · China
- Mar 4, 2024Phase 2 study in Bronchiolitis Obliterans SyndromeNCT06300320 · 65 planned · China
- Apr 25, 2024Phase 1 study in Primary MyelofibrosisNCT06388759 · 9 enrolled · China
- Sep 13, 2024Phase 1 study in Primary MyelofibrosisNCT06598956 · 32 enrolled · China
- Dec 8, 2025Phase 1 study in Mass Balance of [14C] TQ05105 in Healthy Chinese SubjectsNCT07293390 · 6 enrolled · China
- Mar 14, 2026Phase 1 study in Primary MyelofibrosisNCT07480824 · 24 planned · China
- Apr 17, 2026Phase 2 study in Primary MyelofibrosisNCT07551427 · 51 planned · China
- May 20, 2026Phase 1 study in Primary MyelofibrosisNCT07608666 · 17 enrolled · China
- Jul 13, 2026Phase 1 study in Primary MyelofibrosisNCT07708272 · 60 enrolled · China
Ahead
- Dec 2026Primary completion: phase 1 study in Primary MyelofibrosisNCT07708272
- Dec 2026Primary completion: phase 1 study in Primary MyelofibrosisNCT07608666
- Dec 2026Primary completion: phase 2 study in Primary MyelofibrosisNCT06122831
- Nov 2027Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeNCT06300320
TargetBeta
“JAK/ROCK抑制剂”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2), with potential antineoplastic activity. Upon oral administration, JAK2 inhibitor TQ05105 inhibits JAK2 activity, thereby preventing the activation of the JAK/STAT (signal transducer and activator of transcription) signaling pat…”NCIt, read by Claude
“An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2), ”NCIt, by rule
Other programs on JAK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| baricitinibrule | Eli Lilly | phase 4 | 59 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| pacritinibrule | Swedish Orphan Biovitrum | phase 3 | 18 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
| flonoltinibrule | Chengdu Zenitar Biomedical Technology | phase 3 | 7 |
| flonoltinib maleaterule | Chengdu Zenitar Biomedical Technology | phase 2 | 2 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07708272Primary Myelofibrosis · China | 1 | Active, not recruiting | Dec 2026 | 60 |
| NCT07608666Primary Myelofibrosis · China | 1 | Active, not recruiting | Dec 2026 | 17 |
| NCT07551427Primary Myelofibrosis · China | 2 | Recruiting | Jun 2028 | 51 |
| NCT07480824Primary Myelofibrosis · China | 1 | Recruiting | Oct 2026 | 24 |
| NCT07293390Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects · China | 1 | Completed | Apr 8, 2024 | 6 |
| NCT06598956Primary Myelofibrosis · China | 1 | Completed | Mar 17, 2025 | 32 |
| NCT06388759Primary Myelofibrosis · China | 1 | Terminated | Aug 12, 2025 | 9 |
| NCT06300320Bronchiolitis Obliterans Syndrome · China | 2 | Recruiting | Nov 2027 | 65 |
| NCT06122831Primary Myelofibrosis · China | 2 | Recruiting | Dec 2026 | 92 |
| NCT06024915Primary Myelofibrosis · China | 1 | Completed | Jan 29, 2024 | 40 |
| NCT05982106Primary Myelofibrosis · China | 1 | Completed | Jul 28, 2021 | 16 |
| NCT05020652Lymphoma, Follicular · China | 2 | Completed | Oct 15, 2023 | 107 |
| NCT04941404Glucocorticoid-Refractory aGVHD · China | 2 | Terminated | Jul 10, 2023 | 13 |
| NCT04944043Bronchiolitis Obliterans Syndrome · China | 2 | Active, not recruiting | Jun 30, 2023 | 45 |
| NCT04339400Myeloproliferative Disorders · China | 1 | Completed | Mar 17, 2023 | 79 |
| NCT04326348Lymphohistiocytosis, Hemophagocytic · China | 1 | UNKNOWN | Jan 2022 | 40 |
How it is read
Names in the registry
- “TQ05105 tablets”, 6 entries
- “TQ05105”, 5 entries
- “TQ05105 Tablets”, 3 entries
- “TQ05105 Tablets (Rovadicitinib Tablets)”, 1 entry
- “TQ05105 Tablet”, 1 entry
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 9 studies
- Bronchiolitis Obliterans Syndrome, 2 studies
- Myeloproliferative Disorders, 1 study
- Lymphoma, Follicular, 1 study
- Lymphohistiocytosis, Hemophagocytic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.